Aberrant methylation of imprinted genes is associated with

negative hormone receptor status in invasive breast cancer by Barrow, Timothy et al.
Barrow, Timothy, Barault,  L, Ellsworth,  RE, Harris, HR, Binder, AM, Valente, 
AL,  Shriver,  CD  and  Michels,  KB (2015)  Aberrant  methylation  of  imprinted 
genes  is  associated  with  negative  hormone  receptor  status  in  invasive  breast 
cancer. International Journal of Cancer, 137 (3). pp. 537-547. ISSN 0020-7136 
Downloaded from: http://sure.sunderland.ac.uk/8780/
Usage guidelines
Please  refer  to  the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
Aberrant methylation of imprinted genes is associated with 
negative hormone receptor status in invasive breast cancer
Timothy M Barrow1,2,†, Ludovic Barault1,†,#, Rachel E Ellsworth3, Holly R Harris1, 
Alexandra M Binder1, Allyson L Valente4, Craig D Shriver5, and Karin B Michels1,2,*
1Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and 
Reproductive Biology, Brigham and Women’ s Hospital, Harvard Medical School, Boston, MA 
02115, U.S.A
2Instiut für Prävention und Tumorepidemiologie, Universitätsklinikum Freiburg, 79106 Freiburg, 
Germany
3Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military 
Medicine, Windber, PA 15963, U.S.A
4Clinical Breast Care Project, Windber Research Institute, Windber, PA 15963, U.S.A
5Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD 
20889, U.S.A
Abstract
Epigenetic regulation of imprinted genes enables monoallelic expression according to parental 
origin, and its disruption is implicated in many cancers and developmental disorders. The 
expression of hormone receptors is significant in breast cancer as they are indicators of cancer cell 
growth rate and determine response to endocrine therapies. We investigated the frequency of 
aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer 
and examined the association with estrogen and progesterone receptor status. Breast tissue and 
blood from patients with invasive breast cancer (n=38) and benign breast disease (n=30) were 
compared to those from healthy individuals (n=36), matched to the cancer patients by age at 
diagnosis, ethnicity, BMI, menopausal status, and familial history of cancer. DNA methylation 
and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation 
changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 
DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, 
KvDMR in 8%, and SNRPN/SNURF ICR in 4%. Variation of methylation was significantly greater 
in breast tissue from cancer patients than healthy individuals and benign breast disease. Aberrant 
methylation of three or more sites was significantly associated with negative estrogen-alpha 
(Fisher’ s Exact Test, p=0.02) and progesterone-A (p=0.02) receptor status. Aberrant events and 
increased variation of imprinted gene DNA methylation therefore appear to be frequent in invasive 
breast cancer and are associated with negative estrogen and progesterone receptor status, without 
loss of monoallelic expression.
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Introduction
Genomic imprinting is the epigenetic regulation of genes to enable monoallelic expression 
according to parental origin, through differential methylation of regions labeled imprinting 
control regions (ICRs) when established in the germline, or differentially methylated regions 
(DMRs) when established post-fertilization. Loss of imprinting (LOI) is the loss of this 
monoallelic expression, and it is commonly the result of disruption of DNA methylation at 
ICRs and DMRs. LOI is associated with a range of disorders, such as the Beckwith-
Wiedemann, Angelman and Prader-Willi syndromes1,2. Imprinted genes have also been 
implicated in a range of cancers, including those of the breast3 and ovaries4. Their 
expression has been associated with disease progression, including reduced survival in 
pancreatic cancer5 and aggressive prostate cancers6. Aberrant methylation of imprinted 
genes may be an early event involved in neoplastic transformation7, and it has been reported 
that 10% of apparently healthy individuals display LOI of IGF28.
DNA methylation can display stochastic variation, which may facilitate developmental 
plasticity and adaptation to environments, including that of malignant cells in the tumor 
microenvironment9. This variation can be gene-specific, such as that as observed in the 
placenta to enable adaptation to environmental challenges throughout pregnancy10. A 
significantly greater level of variation is observed in tumors, which often constitutes shifting 
in methylation ‘ boundaries’  between CpG islands and shores11. Such events may occur early 
in tumorigenesis, demonstrated by the significantly increased variation observed in cervical 
cells of normal morphology12.
Breast cancers are classified according to the expression of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). ER-
alpha and PR-A expression are determined by immunohistochemistry, with tumors in which 
more than 5– 10% of cells stain positively classified as positive for expression. HER2 
expression is determined by immunohistochemistry, with scores of 0– 3 according to 
intensity of staining, and by fluorescence in situ hybridization (FISH) to detect amplification 
of the gene. Activation of these receptor signaling pathways results in cellular proliferation, 
and they are implicated in the progression of breast and gynecological cancers. 
Approximately two-thirds of tumors display expression of at least one of the hormone 
receptors, and these patients display reduced mortality compared to those who express 
neither13, in part due to the efficacy of endocrine therapies. Triple-negative breast cancers, 
which account for approximately 12– 17% of all cases14, are associated with poor prognosis.
The relation between imprinted genes and hormone receptor status in breast cancer has not 
been well elucidated. Correlations between the methylation of four tumor-suppressor genes 
and the expression of the hormone receptors has been observed3, but similar studies have not 
been performed for imprinted genes. Elucidating such a relationship may provide insight 
into tumorigenesis and the determination of prognostic factors.
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In this study, we investigated the aberrant methylation of nine imprinted regions in samples 
of breast tissue taken from healthy individuals and patients with benign breast disease and 
invasive breast cancer. The interrogated imprinted regions were: DIRAS3 DMR; GRB10 
ICR; H19 ICR; IGF2 DMR0 and DMR2; KvDMR; MEST ICR; PEG3 DMR; and SNPRN/
SNURF ICR. The intra-individual tissue-specificity of the aberrant methylation events was 
determined by comparison of methylation in DNA from breast tissue and peripheral blood 
within individuals. Variation of DNA methylation in imprinted genes and LINE-1 global 
methylation were measured, and possible associations between aberrant methylation and the 
status of the estrogen, progesterone and HER2 receptors in breast cancer patients were 
identified. Finally, we analyzed the allele-specific expression of the genes in order to 
establish the relative impact of the aberrant methylation events.
Materials and methods
Study populations
The Clinical Breast Care Project (CBCP) is a clinical and research program that began 
enrolling patients in 2001. The primary clinical arm of the CBCP was the Clinical Breast 
Care Center at Walter Reed Army Medical Center (Washington DC, USA). Additional 
recruitment centers include the Joyce Murtha Breast Care Center (Windber, PA, USA), and 
the Anne Arundel Medical Center (Annapolis, MD, USA). Enrolled patients were required 
to be 18-years-old or older, mentally competent and willing to provide informed consent, 
and presenting with evidence of possible breast disease, attending for routine screening 
mammograms, or undergoing elective reductive mammoplasty. Patients were provided with 
layered consent forms that included permission to obtain samples of blood, breast and 
metastatic tissues, and a description of the primary research uses. Once informed consent 
was granted, the core questionnaire, with over 500 fields of information, was completed 
with the help of a nurse case manager, and an extensive pathology checklist was completed 
by the dedicated breast pathologist. Ethical approval for the collection of blood and tissue 
samples and their use in this study was provided by the Walter Reed Army Medical Center 
Human Use Committee and Institutional Review Board.
The Susan G. Komen for the Cure Tissue Bank (Indianapolis, IN, USA) is a charitable 
organization that enrolls healthy volunteers to donate blood and up to four breast biopsies. 
Eligible individuals must be at least 18 years of age and able to provide informed consent. 
Volunteers are asked to complete a questionnaire regarding health and lifestyle factors. 
Approval for the collection of blood and tissue, and for their use in this study, was provided 
by the Indiana University Institutional Review Board.
Blood and tissue samples
DNA and RNA from benign and tumor tissue and blood were obtained from the CBCP for 
38 patients with invasive breast cancer and 30 with benign breast disease (13 fibrocystic 
changes, 8 fibroadenoma, 3 post-surgical changes, 2 stromal fibrosis, and 4 other) (Table 1, 
Supplementary Table 1). Genomic DNA was extracted from frozen tumor samples 
following laser microdissection (Leica Microsystems, Wetzlar, Germany) and homogenized 
benign tissue by incubation with proteinase K at 37°C overnight and passage through 
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purification columns (Millipore, Billerica, MA, USA). DNA extractions from blood were 
performed using Clotspin and Puregene DNA purification kits (Qiagen, Valencia, CA, USA) 
according to the manufacturer’ s instructions.
Samples from 36 healthy individuals were obtained from the Susan G. Komen for the Cure 
Foundation Tissue Bank (Table 1). DNA was extracted from 25mg tissue using the QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer’ s protocol, following proteinase K 
digestion at 56°C for 3– 6 hours. RNA extractions were performed using the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’ s protocol, following mechanical disruption of 
25mg tissue in a bead mill. Between 2 and 41µg of DNA isolated from blood was made 
available for this study.
Bisulfite conversion of DNA
250– 500ng of DNA was converted using the EZ DNA Methylation Gold kit (Zymo 
Research, Irvine, CA, USA), according to the manufacturer’ s Alternative 2 protocol, with 
elution in 40µl of elution buffer.
DNA methylation analysis by pyrosequencing
Pyrosequencing was performed on the Pyromark Q24 Pyrosequencer (Qiagen). Assays were 
designed using the PyroMark Assay Design and PyroMark Q24 software programs 
(Qiagen), with the exceptions of those for H19 ICR, IGF2 DMR0 and IGF2 DMR2, which 
have previously been reported15– 17. Nine DMRs/ICRs were analyzed: DIRAS3 DMR (5 
CpG dinucleotides); GRB10 ICR (6 CpGs); H19 ICR (8 CpGs); IGF2 DMR0 (6 CpGs); 
IGF2 DMR2 (7 CpGs); KvDMR (9 CpGs); MEST ICR (9 CpGs) PEG3 DMR (6 CpGs); and 
SNRPN/SNURF ICR (8 CpGs) (Supplementary Table 2).
Regions of interest were amplified by polymerase chain reaction (PCR), using 3µl of 
bisulfite-treated DNA and 0.2µM of each primer with HotStar Taq Plus Master Mix 
(Qiagen) in a final volume of 20µl. Pyrosequencing was performed according to the 
manufacturer’ s instructions. Duplicate bisulfite-conversions were run for each sample and 
mean methylation levels were calculated across all CpG sites per replicate. Studies in 
healthy human tissues have reported methylation levels of between 30 and 70% at DMRs 
and ICRs16,17, and we therefore defined hypomethylation as values below 30% and 
hypermethylation as values above 70%. It was not possible to ascertain methylation values 
for all samples.
Identification of allelic origins of mRNA
Allele-specific expression was performed by pyrosequencing, using single nucleotide 
polymorphisms (SNPs) to determine the allelic origins of mRNA transcripts in heterozygous 
patients, identified by pyrosequencing using 10ng of DNA from blood. For heterozygous 
individuals, 20ng of RNA was reverse-transcribed using the iScript cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, USA) according to the manufacturer’ s instructions, and 
2µl of cDNA used for PCR-based amplification prior to allele quantification by 
pyrosequencing. Primer sequences and SNPs are provided in Supplementary Table 2.
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Gene expression microarray data
Expression data for ten genes (DIRAS3, DNMT1, DNMT3A, DNMT3B, GRB10, IGF2, 
KCNQ1, MEST, PEG3, and SNRPN) from 302 breast tumors were made available by the 
Walter Reed Army Medical Center (Washington DC, USA). Of the tumors, 199 were ER-
positive and 103 were ER-negative, and 153 were PR-positive and 149 PR-negative.
Statistical analysis
Correlations between DNA methylation and age at diagnosis were calculated by Pearson 
correlation for all genes except GRB10, for which Spearman’ s rank correlation was used as 
the data was not normally distributed. Associations with tumor stage, receptor status and 
familial history of cancer were calculated by ANOVA. For the FAM group, associations 
were calculated by Fisher’ s exact test, and associations with age at diagnosis calculated by t-
test or Wilcoxon rank sum test, according to the distribution of the data. P values below 0.05 
were deemed statistically significant.
For the modeling of variation, deviation was calculated as the absolute difference between 
the median methylation level in blood or breast tissue from healthy individuals and the 
methylation level for the individual. This was conducted for each gene, for comparisons of 
samples from patients with benign breast disease and cancer to the healthy controls, in both 
blood and breast tissue. A general linearized model was used to model deviation with a 
gamma distribution, and a log link. Model coefficients and 95% confidence intervals were 
exponentiated to give the relative change in deviation between tissues. The adjusted model 
controlled for family history (binary), menopausal status (binary), BMI category (normal, 
<25; overweight, 25 –  30; obese, >30), and age (continuous). Results were corrected for 
multiple hypothesis testing using the Bonferroni correction, and p values below 0.05 deemed 
statistically significant.
Results
Aberrant DNA methylation of imprinted genes is a frequent event in breast tumors
We investigated the DNA methylation at nine imprinted regions in breast tissue and 
peripheral blood from 36 healthy individuals, 30 patients with benign breast disease and 38 
with invasive cancer. We have previously reported methylation levels at six of the imprinted 
regions (GRB10 ICR, H19 ICR, IGF2 DMR0, IGF2 DMR2, KvDMR, and SNRPN/SNURF 
ICR) in patients with benign breast disease and breast cancer18, and we integrated these 
results with methylation levels measured in healthy individuals to identify the relative 
frequency of aberrant methylation (hypo- and hypermethylation) in the disease states.
In breast tissue, median methylation levels were close to the expected 50% with the 
exception of the IGF2 sites, which also displayed greater disparities in the median levels 
between normal, benign and tumor tissue (Figure 1). Aberrant methylation was frequently 
observed in invasive breast cancer, observed at IGF2 DMR2 in 59% of patients, IGF2 
DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR 
in 19%, H19 ICR in 18%, KvDMR in 8%, and SNRPN/SNURF ICR in 4% (Supplementary 
Table 3). Hypomethylation was more common than hypermethylation at all sites except 
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MEST ICR and PEG3 DMR, and was not associated with whether the genes are maternally 
or paternally expressed. Among patients with benign breast disease, aberrant methylation 
was only observed at IGF2 DMR2, which was hypomethylated in 12 of the 26 successfully-
analyzed samples. No aberrant methylation was observed in healthy individuals at seven of 
the imprinted regions, with IGF2 DMR0 hypermethylated in one sample and IGF2 DMR2 
hypomethylated in three.
To determine the intra-individual tissue specificity of the methylation changes observed in 
breast tumors, we analyzed peripheral blood samples taken from the same individuals. 
Median values for all nine regions were between 39.1 and 53.6% across the three groups 
(Supplementary Table 3). No samples met the criteria of being hypo- or hypermethylated, 
indicating that the aberrant methylation events were unique to breast tissue.
Variation of DNA methylation is significantly greater in breast tissue and blood from 
patients with invasive breast cancer and benign breast disease
Variation of DNA methylation in the healthy and disease states was estimated by the 
absolute difference between the methylation level in an individual and the median level 
measured in breast tissue or peripheral blood from healthy individuals, with the latter 
representing the normal value. The mean deviation from the median methylation levels 
observed in normal breast tissue was greatest in invasive tissue, ranging from 6.6% for 
SNRPN/SNURF ICR to 23.0% for IGF2 DMR0 (Figure 2A, Supplementary Table 4A). The 
mean deviations were lowest in normal breast tissue, where they were under 2.0%, with the 
exceptions of IGF2 DMR0 (4.2%) and IGF2 DMR2 (5.5%). Benign breast tissue displayed 
intermediate values, with median deviation ranging from 2.5% for DIRAS3 DMR to 11.2% 
for IGF2 DMR2.
The mean deviations in healthy individuals were lower in blood than in breast tissue, with 
the exceptions of PEG3 DMR in healthy individuals and DIRAS3 DMR in patients with 
benign breast disease (Figure 2A, Supplementary Table 4A). The deviations were greatest in 
blood from invasive breast cancer patients, where median deviations ranged between 1.7% 
and 6.6%. The values ranged between 1.5 and 6.7% among benign breast disease patients, 
and between 0.7 and 3.2% in healthy individuals.
The relative deviations from the median methylation levels were significantly greater at all 
interrogated regions in tumor tissue than in normal breast tissue, ranging from 2.6-fold 
(IGF2 DMR2) to 9.7-fold (DIRAS3 DMR) greater (Figure 2B, Supplementary Table 4B). 
When the model was adjusted for the age, BMI, menopausal status and familial history of 
cancer of the individuals, statistical significance was retained at all sites. Variation was also 
significantly greater in benign breast disease tissue than normal breast tissue for all DMRs 
except DIRAS3 DMR, with the relative deviations between 1.5-fold (DIRAS3 DMR) and 7.5-
fold (SNRPN/SNURF ICR) greater. Significance was retained for all sites except IGF2 
DMR0 and MEST ICR with the adjusted model.
Significantly greater variation of methylation was similarly observed in peripheral blood. 
Mean deviations in blood from patients with invasive breast cancer were between 1.3-fold 
(DIRAS3 DMR) and 7.4-fold (SNRPN/SNURF ICR) greater than in healthy individuals, and 
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were significant for GRB10 ICR, KvDMR, PEG3 DMR and SNPRN/SNURF ICR. In the 
adjusted model, the relative changes were significant for GRB10 ICR, IGF2 DMR2, PEG3 
DMR and SNRPN/SNURF ICR (Supplementary Table 4B). Mean deviations were also 
between 1.3-fold (IGF2 DMR0) and 7.5-fold (SNRPN/SNURF ICR) greater in blood taken 
from patients with benign breast disease than in healthy individuals (Figure 2B, 
Supplementary Table 4B). The differences were significant for GRB10 ICR, MEST ICR, 
PEG3 DMR and SNRPN/SNURF ICR in both the adjusted and unadjusted models 
(Supplementary Table 4B).
Aberrant DNA methylation is Associated with Hormone Receptor Status
We investigated possible associations between the measured methylation values at each 
imprinted loci and expression of the estrogen (ER), progesterone (PR) and HER2 receptors 
(details in Supplementary Table 1). Hypermethylation of PEG3 DMR (ANOVA, p<0.01) 
and IGF2 DMR0 (p=0.04) were associated with negative ER status, while hypermethylation 
of PEG3 DMR (p=0.02) and MEST ICR (p=0.03) were associated with negative PR status 
(Table 2). No associations were observed between the methylation of imprinted genes and 
the expression of HER2 or tumor stage.
Frequently altered methylation (FAM) and hormone receptor status
Twelve of the invasive tumors analyzed displayed aberrant methylation of at least three of 
the imprinted regions that were interrogated. We categorized these together as “ frequently 
altered methylation”  (FAM). FAM was associated with negative ER (Fisher’ s exact test, 
p=0.02) and PR status (p=0.02), but not HER2 (p=0.32) or tumor stage (p=0.15) (Table 2). 
All five triple-negative tumors displayed aberrant methylation at three or more sites.
Methylation at LINE-1 repetitive elements was measured in breast tissue from patients with 
benign breast disease and invasive cancer, and analyzed according to the FAM grouping of 
cancers and the expression of the estrogen receptor (Figure 3A– B). Greater variation was 
observed in breast tumors, with values ranging between 50 and 79% compared to 69– 77% in 
benign breast disease tissue (Figure 3A). Within the tumor samples, median values were 
similar in the FAM (71.1%) and non-FAM (71.8%) groups, but slightly higher in ER-
negative tumors (73.2%) than in ER-positive ones (71.5%). Tumors expressing the estrogen 
receptor also displayed a greater range of values (50 to 76%) in comparison to those that do 
not (66 to 79%) (Figure 3B).
Monoallelic expression of imprinted genes is maintained in breast tumors
To determine the impact of the observed methylation changes, we examined the allele-
specific expression of the genes. Firstly, we genotyped the cancer patients for SNPs in the 
DIRAS3, GRB10, H19, IGF2, MEST and PEG3 genes. KCNQ1 and SNRPN were not 
analyzed due to the infrequency of aberrant methylation in the tumor samples. We identified 
24 patients who were heterozygous for SNPs in the PEG3 gene, 18 for IGF2, 14 for GRB10, 
10 for H19, 7 for MEST and 4 for DIRAS3.
Monoallelic expression, defined here as >85% of transcripts from a single allele, was almost 
exclusively retained (Figure 4). PEG3 was monoallelically expressed in 17 of 18 patients 
Barrow et al. Page 7
Int J Cancer. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
with normal methylation levels and 5 of 6 patients displaying hypermethylation of the gene 
(Figure 4A). In the other two patients, 71 and 81% of transcripts originated from a single 
allele. Monoallelic expression was observed in five of the seven patients informative for 
MEST, with 79% and 80% of transcripts expressed from a single allele in the other two 
patients (Figure 4B). All 18 patients informative for IGF2 monoallelically expressed the 
gene, including the 4 patients with hypomethylation of DMR0 and 4 displaying 
hypomethylation of DMR2 (Figures 4C– D). Monoallelic expression of H19 was observed in 
8 of the 10 informative patients, including the one displaying hypomethylation of the gene 
(Figure 4E). Two individuals displayed biallelic expression despite normal methylation 
profiles, with the relative expression of the two alleles 64/36% and 55/45%. GRB10 
displayed a markedly different pattern of expression, with the proportional expression of the 
two alleles between 51/49% and 60/40% in 7 of the 14 informative patients, and only three 
patients expressed >70% of transcripts from a single allele (Figure 4F). DIRAS3 results are 
not shown due to the lack of informative patients.
GRB10 and IGF2 are differentially expressed in ER-positive tumors
To further examine the relation between hormone receptor status and the expression of 
imprinted genes, we utilized gene expression microarray data from 302 breast tumor 
samples, made available through the Walter Reed Army Medical Center. Expression of 
seven of the imprinted genes was analyzed between ER-positive (n=199) and ER-negative 
(n=103) tumors, and between PR-positive (n=153) and PR-negative (n=149) tumors. H19 
expression was not covered by the array. GRB10 expression was 1.4-fold lower 
(p=1.7×10−10) and IGF2 expression was 1.9-fold higher (p=6.0×10−7) in ER-positive 
tumors (Supplementary Table 5). No significant differences were observed by PR status.
Expression of DNA methyltransferases are not associated with hormone receptor status
To investigate how DNA methylation at imprinted regions may be related to estrogen and 
progesterone receptor status, we utilized gene expression microarray data from 302 breast 
tumor samples (Supplementary Table 5). We observed no significant differences in the 
expression of the DNMT1 (−1.1 fold-change), DNMT3A (−1.3 fold-change) and DNMT3B 
(−1.6 fold-change) genes in ER-positive tumors in comparison to ER-negative ones. 
Similarly, no significant difference was observed for any of the three genes (−1.1, −1.1 and 
−1.3 fold-changes respectively) in PR-positive tumors versus PR-negative tumors.
Discussion
We found the imprinted regions DIRAS3 DMR, GRB10 ICR, H19 ICR, IGF2 DMR0, IGF2 
DMR2, MEST DMR and PEG3 DMR to be frequently aberrantly methylated in the patients 
with invasive breast cancer included in this study. These alterations are highly tissue- and 
tumor-specific, with no such changes observed in blood and only highly infrequently in 
normal breast tissue and benign breast disease tissue. This result confirmed our previous 
Supplementary Table 5: Gene expression by hormone receptor status Gene expression microarray data from 302 breast tumor samples. 
Fold-change in expression (positive versus negative) and statistical significance are provided for ten genes (n/s = not significant). H19 
was not present on the microarray. Of the 302 tumors, 199 were ER-positive and 103 were ER-negative, while 153 were PR-positive 
and 149 PR-negative.
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work in which we observed no correlation between the methylation at six imprinted regions 
in breast tumors and matched peripheral blood18. Variation of DNA methylation was 
significantly greater at all nine imprinted regions in breast tumors comparison to normal 
breast tissue, and at eight (unadjusted model) and six (adjusted) of the regions in benign 
breast disease tissue. Aberrant methylation of more than three of the imprinted regions was 
significantly associated with negative status of the estrogen and progesterone receptors. 
Despite this disruption of DNA methylation, monoallelic expression of the imprinted genes 
was frequently maintained.
This is the first study to identify a correlation between the methylation of imprinted genes 
and expression of the estrogen and progesterone receptors in breast cancer. ER-positive and 
ER-negative tumors have distinct global DNA methylation profiles19,20, and work in animal 
models and cell lines has demonstrated that hormone receptor signaling, including that by 
agonists such as bisphenol A, can affect the expression of DNA methyltransferases21– 23 and 
directly lead to changes in the methylation and expression of imprinted genes such as IGF2 
and PEG321,24,25. Furthermore, in vitro studies have shown that expression of the imprinted 
gene CDKN1C is repressed via epigenetic mechanisms induced by estrogen signaling in 
breast cancer cell lines26. Taken together with our observations in primary human breast 
tumors, this may suggest that normal hormone receptor signaling is important for the 
maintenance of methylation for imprinted genes, and absence of such signaling may result in 
aberrant regulation in malignant cells. Interestingly, in vitro work has demonstrated that 
mutations in the DNMT1 gene lead to loss of IGF2 and PEG3 imprinting, with KCNQ1 less 
susceptible to such changes27, and we similarly observed that aberrant methylation of the 
IGF2 and PEG3 DMRs was substantially more frequent than at the KvDMR (Figure 2A), 
although we did not observe an impact upon allele-specific expression. However, we did not 
observe significantly different expression of DNMT1, DNMT3A or DNMT3B between ER-
positive and ER-negative tumors (Supplementary Table 5). Our findings may either suggest 
that the relation between DNA methylation at imprinted loci and ER signaling may be 
confined to a subset of ER-negative tumors, or that the association is independent of the 
regulation of DNA methyltransferase expression reported in vitro.
Similar associations between DNA methylation and hormone receptor status have been 
identified for non-imprinted genes3,28. However, the differential methylation of alleles and 
roles in regulating proliferation and differentiation make imprinted genes particularly 
susceptible to driving tumorigenesis. Indeed, changes in the methylation of imprinted genes 
have been reported in esophageal dysplasia29 and localized ovarian tumors30. As the ER is 
frequently silenced by promoter methylation in breast tumors31, it is not clear whether 
hormone receptor status is the cause or product of wider epigenetic dysregulation. Further 
work is required to establish whether a subset of breast tumors may display a characteristic 
epigenetic profile. The identification of such a group may open new therapeutic options to 
the patients, including the combined use of 5-Azacytidine and S-adenosylmethionine, which 
inhibit the growth of breast cancer cells32.
We observed increasing variation in DNA methylation from normal breast tissue to benign 
breast disease to cancer. This finding is consistent with observations made by Teschendorff 
and colleagues, who suggested increased variability as a marker for early detection of 
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cervical cancer, even being present in cytologically-normal cells of individuals who later 
developed12. Thus, this variability may be a key part of the neoplastic transformation 
process. It may arise through the shifting of methylation boundaries, rather than gene-
specific changes11. As we have employed a candidate-gene approach, with comparatively 
short reads obtained by pyrosequencing, it remains uncertain whether this variability is 
confined to the interrogated DMRs or whether it may be the result of wider boundary-shifts. 
Furthermore, the degree of variation of methylation within the tumors remains unknown. 
Mosaicism is a well-known phenomenon in cancer, and may provide some explanation for 
our observations.” .
Increased variability in DNA methylation has been proposed as a blood-based marker for 
ovarian cancer33, and we similarly observed significantly increased variation in both the 
adjusted and unadjusted models at GRB10 ICR, PEG3 DMR and SNRPN/SNURF ICR in 
peripheral blood from cancer patients. However, the statistical significance may be the 
product of the tight clustering of values observed in healthy individuals, with mean 
deviations from median values below 3.5% at all sites. While group differences may be 
significant, the value for risk prediction in individuals remains uncertain.
The sites displaying the most frequent aberrant methylation and greatest variation were the 
two IGF2 DMRs. IGF2 is a widely studied oncogene that stimulates cellular proliferation, 
and hypomethylation of DMR0 is associated with poor prognosis with colorectal cancer34. 
We observed that hypomethylation of DMR0 was associated with negative ER status, which 
is itself associated with poor prognosis in breast cancer13. The observed frequency of 
hypomethylation was similar to that reported elsewhere16. While loss of IGF2 imprinting in 
peripheral blood has been suggested as a potential diagnostic marker for colorectal cancer8, 
changes in methylation at DMR0 were specific to the tumors, and we have previously 
reported a lack of correlation between blood and tumor tissues18. This may suggest that 
peripheral blood cannot serve as a surrogate tissue, although correlations may be gene-
specific, as there is evidence that methylation of ATM35 and targets of ER signaling36 could 
be used as blood-based markers of breast cancer risk.
Interestingly, the disruption of methylation did not impact upon allele-specific expression in 
the tumors, with monoallelic expression almost exclusively retained. Conversely, our results 
suggest that GRB10, which is monoallelically expressed in fetal brain tissues and placenta 
but not in other fetal tissues37– 39, may not be imprinted in breast tissue in adult humans. 
Loss of IGF2 imprinting has been reported in colorectal and ovarian tumors8,40 and PEG3 in 
gynecological cell lines41, but we observed >77% of transcripts originating from a single 
allele in all the tumor samples informative for these genes. Furthermore, our observation of 
monoallelically-expressed MEST in all seven informative patients is in direct contrast to 
findings elsewhere of biallelic expression in breast cancer patients42. While H19 was 
biallelically expressed in two patients, methylation of the H19 ICR was not disrupted in 
these tumors, suggesting an alternative cause of LOI. Hypomethylation of H19 ICR has been 
correlated with LOI in lung cancer43, but there is evidence that the IGF2/H19 competition 
model does not hold true in colorectal44,45 and ovarian40 tumors. Similarly, a lack of 
correlation has been observed between hypomethylation of IGF2 DMR0 and LOI in colon 
and breast tumors16, while hypomethylation of IGF2 DMR0 in ovarian serous tumors 
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increases overall expression but does not result in biallelic expression40. While the classical 
model of imprinting suggests that monoallelic expression is the product of differential 
methylation of the two alleles, this does not appear to hold as strongly in humans as it does 
in mice. However, it is not clear why the frequency of LOI is lower here than reported 
elsewhere, as this phenomenon has been reported in primary breast tumors42,46. An 
alternative explanation for our observations could be that the changes in DNA methylation 
are confined to a subset of cells in which expression is silenced. As pyrosequencing enables 
the measurement of the relative abundance of the transcripts from the two alleles, but not 
their overall quantity, our observations of monoallelic expression being retained may be 
based upon an inability to detect silencing of the expressed allele in the affected cells.
There have been few studies investigating epigenetic dysregulation in benign breast disease. 
Although proliferative benign disease is associated with a greater relative risk of developing 
cancer47, we have previously reported no significant difference in methylation at six of the 
imprinted loci between proliferative and non-proliferative conditions18. There is limited 
evidence of loss of IGF2 imprinting in benign breast disease48, and we observed that 
hypomethylation of IGF2 DMR2 was highly frequent. Although aberrant methylation was 
not observed at the other regions, there was significantly greater variability in methylation at 
six (adjusted model) and eight (unadjusted) sites, and increased variability in cytologically-
normal epithelial cells is associated with increased risk of developing neoplasia12. Further 
work is required to establish the possible role of epigenetic dysregulation in the etiology of 
benign breast disease.
A limitation of our study is the potential difference in the proportions of cell types between 
the normal, benign and tumor tissues. Laser-microdissection of the tumor tissue was 
performed to isolate malignant cells, but was not conducted with normal tissue to enrich the 
epithelial cells. While median DNA methylation values in normal tissue were consistently 
close to the expected 50% value, we cannot rule out that the variation modeling may have 
been affected. We also cannot exclude the possibility of copy number changes influencing 
measured methylation values in the samples, as insufficient quantities of DNA remained 
following epigenetic analyses to also perform genetic analyses. Furthermore, the number of 
samples in this study may also have precluded us from identifying other significant 
correlations between DNA methylation and tumor subtype, such as with triple-negative 
tumors. A particular strength of this study is the access to breast tissue from healthy 
individuals. There is evidence that histologically-normal tissue adjacent to breast tumors can 
possess genomic alterations seen in the cancer49, and therefore it is important to use breast 
tissue from healthy women as controls in order to accurately identify changes associated 
with malignant transformation. A further strength was the availability of both DNA and 
RNA from blood and breast tissue that has enabled us to investigate the specificity of 
changes in DNA methylation and the effect upon allele-specific expression.
This is the first study, to our knowledge, to identify an association between the aberrant 
methylation of imprinted genes and hormone receptor status in breast cancer. We have 
established that 1) aberrant events in the DNA methylation of these imprinted regions are 
frequent in breast tumors, 2) variation is greater in both breast tissue and in blood from 
patients with invasive breast cancer than in healthy individuals, and 3) aberrant changes in 
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DNA methylation are associated with hormone receptor status in the tumors. Further work is 
required to establish whether such methylation changes are the direct result of loss of 
hormone receptor signaling or are the product of more widespread changes in global DNA 
methylation.
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Refer to Web version on PubMed Central for supplementary material.
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Impact: This is the first study, to our knowledge, to identify an association between the 
aberrant DNA methylation of imprinted genes and negative status of the estrogen and 
progesterone receptors in breast cancer. Furthermore, we describe how variation in 
methylation of these genes increases from normal breast tissue to benign breast disease to 
cancer. Our findings may imply an important role for epigenetic disruption of imprinted 
genes in the development of different breast cancer subtypes.
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Figure 1. DNA Methylation at nine imprinted regions in breast tissue from patients and healthy 
individuals
Measured methylation values in breast tissue for DIRAS3 DMR (A), GRB10 ICR (B), H19 
ICR (C), IGF2 DMR0 (D), IGF2 DMR2 (E), KvDMR (F), MEST ICR (G), PEG3 DMR (H) 
and SNRPN/SNURF ICR (I) in healthy individuals and patients with benign breast disease 
and invasive cancer. Boxes correspond to the median and interquartile range, and the 
whiskers to the full range of measured values. Statistically significant differences are 
indicated (Mann-Whitney U Test; * = p < 0.05; ** = p <0.01; *** = p < 0.0005; **** = p < 
0.0001).
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Figure 2. Variation in DNA methylation in breast tissue and blood
(A) Mean deviation from the measured median value in normal breast tissue or blood from 
healthy individuals for each of the nine imprinted regions. Results are from patients with 
invasive cancer (• ), benign breast disease (×) and healthy individuals (−). (B) Change in 
mean deviation from median methylation values measured in normal tissue and blood, 
relative to values observed in normal breast tissue and blood from healthy individuals. 
Results for cancer patients from the unadjusted (• ) and adjusted (߷) models, and from 
patients with benign breast disease in the unadjusted (×) and adjusted (+) models.
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Figure 3. DNA methylation at LINE-1 elements in benign breast disease tissue and breast tumors
Results are displayed in relation to the FAM status of the tumors (A) and by expression of 
the estrogen receptor (ER) (B). Boxes correspond to the median and interquartile range, and 
the whiskers to the full range of measured values. Statistically significant differences are 
indicated (Mann-Whitney U Test; * = p < 0.05; ** = p <0.01; *** = p < 0.0005; **** = p < 
0.0001).
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Figure 4. Expression of imprinted genes relative to DNA methylation status
Allelic-expression of PEG3 (A), MEST (B) IGF2 relative to DMR0 (C) and DMR2 (D), H19 
(E) and GRB10 (F). For each patient, DNA methylation values (• ) and allelic expression (bar 
graph) are provided. Expression values correspond to the percentage of transcripts 
originating from the more transcribed allele.
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Table 1
Characteristics of the participants
The characteristics of the individuals involved in the study from whom samples of breast tissue and blood 
were taken. Healthy individuals were matched to the cancer patients by age, ethnicity, BMI, menopausal status 
and familial history of cancer. The ages and BMIs are the means of each category. Post-menopausal status 
includes patients who were surgically post-menopausal, such as following hysterectomy. Familial history of 
cancer refers to primary and secondary history. For one healthy individual, the familial history was not known. 
BMI: body mass index.
Healthy Benign breast disease Invasive cancer
Number of participants 36 30 38
Age at diagnosis 50.3 47.5 51.5
Ethnicity (%)
White 29 (80.6) 21 (70.0) 28 (73.7)
African-American 7 (19.4) 5 (16.7) 7 (18.4)
Other 0 (0.0) 4 (13.3) 3 (7.9)
BMI 28.0 25.2 28.5
Menopausal status (%)
Pre- 21 (58.3) 20 (66.7) 19 (50.0)
Post- 15 (41.7) 10 (33.3) 19 (50.0)
Familial history of cancer (%) 17 (48.6) 11 (36.7) 18 (47.4)
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Table 2
Correlations between DNA methylation of imprinted genes and tumor pathology
Correlations between aberrant methylation of nine imprinted genes and the tumor and patient characteristics were identified using the Pearson correlation 
(age at diagnosis) and ANOVA (tumor stage, receptor status and familial history of cancer). For the frequently altered methylation group (FAM, tumors 
with more than three aberrantly methylated imprinted regions), Fisher’ s exact test was used to identify associations with tumor stage, receptor status and 
familial history, while a t-test or Wilcoxon rank sum test was used to identify associations with age at diagnosis. P values are provided with rho values 
below where appropriate. Statistically significant (p < 0.05) associations are highlighted in bold.
Imprinting
regions
Age at diagnosis
(rho values)
Tumor
stage ER PR ER/PR HER2
Familial
history
DIRAS3 DMR 0.88 (−0.04) 0.85 0.20 0.36 0.44 0.53 0.55
GRB10 ICR 0.96 (<0.01) 0.06 0.09 0.45 0.21 0.16 0.20
H19 ICR 0.39 (−0.16) 0.29 0.67 0.52 0.45 0.57 0.89
IGF2 DMR0 0.18 (−0.28) 0.15 0.04 џ 0.98 0.02 џ 0.22 0.23
IGF2 DMR2 0.49 (−0.15) 0.08 0.96 0.65 0.82 0.70 0.32
KvDMR 0.45 (−0.15) 0.24 0.70 0.31 0.59 0.33 0.38
MEST ICR 0.94 (−0.01) 0.58 0.23 0.03 џ 0.10 0.40 0.42
PEG3 DMR 0.33 (−0.18) 0.71 <0.01 џ 0.02 џ 0.01 џ 0.99 0.66
SNRPN ICR 0.58 (0.12) 0.89 0.89 0.46 0.56 0.61 0.66
FAM 0.91 0.15 0.02 - 0.02- 0.02- 0.32 0.28
џ
Down-arrows indicate reduced levels of methylation with expression of the estrogen or progesterone receptor. For the FAM grouping,
−
minus symbols indicate that aberrant methylation is associated with negative status of the receptor.
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